Solid Tumor, Adult Clinical Trial
Official title:
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion, and Dose-Randomization Study of IO 108 as Monotherapy and in Combination With Either Pembrolizumab or Cemiplimab in Adult Patients With Advanced Solid Tumors
Verified date | March 2024 |
Source | Immune-Onc Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.
Status | Completed |
Enrollment | 91 |
Est. completion date | May 31, 2024 |
Est. primary completion date | April 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients must be =18. 2. Has any histologically- or cytologically confirmed advanced/metastatic solid tumor by pathology report and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinical benefit. Solid tumors of any type are eligible for enrollment. Patients with asymptomatic central nervous system (CNS) disease may be enrolled. 3. Patient has measurable disease by Response Evaluation in Solid Tumors version 1.1 (RECIST 1.1) as assessed by local site. 4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 5. Patients must have adequate hepatic function and renal function. Exclusion Criteria: 1. Patients who previously received a monoclonal antibody therapy targeting LILRB2/ Immunoglobulin-Like Transcript 4 (ILT4) (including IO-108). 2. Patients who received a biologic systemic anti-cancer therapy <4 weeks or 5 half-lives prior to their first day of study drug administration, or a small molecule systemic anti-cancer therapy or definitive radiotherapy <2 weeks or 5 half-lives prior to their first day of study drug administration or have not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or better from any adverse events (AEs) that were due to prior cancer therapeutics. Palliative radiation is allowed within 2 weeks of the first day of study drug administration. 3. Requires systemic corticosteroids at a dose of >10 mg prednisone or the dose equivalent to other systemic corticosteroid. 4. History of radiation pneumonitis, non-infectious pneumonitis or interstitial lung disease. 5. Symptomatic CNS spread of tumor. 6. History of Grade > 3 immune-related AEs with any prior immunotherapy. 7. Patients with uncontrolled, active infection. 8. Patients with known hypersensitivity to any of the components of the IO-108 formulation or pembrolizumab. 9. Active known malignancy with the exception of any of the following: 1. Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; 2. Low-risk prostate cancer for which observation or hormonal therapy only is indicated; 3. Any other malignancy treated with curative intent with the last treatment completed =6 months before study initiation (with the exception of hormonal therapies when indicated). 10. Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan =28 days prior to Cycle 1 Day 1 (C1D1). 11. Any of the following in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, clinically significant arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch block or controlled atrial fibrillation are allowed. 12. Ongoing cardiac dysrhythmias of Grade 2 or higher per NCI CTCAE, Version 5.0. 13. Known active bacterial, viral, and/or fungal infection including hepatitis B (HBV), hepatitis C, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or acquired immunodeficiency syndrome (AIDS)-related illness. 14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study. |
Country | Name | City | State |
---|---|---|---|
United States | Texas Oncology - Austin (142) (USOR SITE) | Austin | Texas |
United States | Beverly HIlls Cancer Center (129) | Beverly Hills | California |
United States | St. Vincent - Frontier Cancer Center (135) | Billings | Montana |
United States | Gabrail Cancer Center (128) | Canton | Ohio |
United States | Oncology Hematology Care Clinical Trials, LLC (144) (USOR SITE) | Cincinnati | Ohio |
United States | Maryland Oncology Hematology, PA (145) (USOR SITE) | Columbia | Maryland |
United States | Texas Oncology - Baylor Charles A. (143) (USOR SITE) | Dallas | Texas |
United States | Karmanos Cancer Institute (126) | Detroit | Michigan |
United States | NEXT Oncology-Virginia (121) | Fairfax | Virginia |
United States | University of Florida (125) | Gainesville | Florida |
United States | MD Anderson Cancer Center (101) | Houston | Texas |
United States | Oncology Consultants, P.A. (138) | Houston | Texas |
United States | Carolina BioOncology (102) | Huntsville | North Carolina |
United States | Indiana University Melvin and Bren Simon Comprehensive Cancer Center (123) | Indianapolis | Indiana |
United States | Florida Cancer Specialists (134) | Lake Mary | Florida |
United States | Rocky Mountain Cancer Centers, LLP (141) (USOR SITE) | Lone Tree | Colorado |
United States | NYU Langone Health (131) | New York | New York |
United States | Memorial Cancer Institute (146) | Pembroke Pines | Florida |
United States | UPMC Hillman Cancer Center (105) | Pittsburgh | Pennsylvania |
United States | Providence Cancer Institute (104) | Portland | Oregon |
United States | Florida Cancer Specialists & Research Institute (103) | Sarasota | Florida |
United States | Swedish Cancer Institute (147) | Seattle | Washington |
United States | Hematology Oncology (136) | Stuart | Florida |
United States | Arizona Oncology Associates, PC-HOPE (140) (USOR SITE) | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Immune-Onc Therapeutics | Regeneron Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Receptor occupancy of IO-108 in IO-108 monotherapy and IO-108+pembrolizumab | To assess target engagement via determining Leukocyte Immunoglobulin-Like Receptor subfamily B2 (LILRB2) occupancy by IO-108 in peripheral blood myeloid cells, as expressed by % of target receptor engagement | From the first dose of IO-108 till 21 days after | |
Primary | Incidence of treatment-emergent and serious adverse events in patients treated with IO-108 and IO-108+pembrolizumab | safety and tolerability as measured by the incidence of treatment-emergent adverse events and serious adverse events | From first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment date or disease progression whichever is earlier | |
Primary | Determine MTD (maximum tolerated dose) through assessment of dose-limiting toxicities (DLT) | MTD will be determined through observation of pre-determined DLTs in each dose cohort | From the first dose of IO-108 until 21 days post-treatment | |
Primary | Assess safety and tolerability of the IO-108 RP2D as monotherapy or in combination with either pembrolizumab or cemiplimab in patients with solid tumors | safety and tolerability as measured by the incidence of treatment-emergent adverse events and discontinuation due to TEAEs | From the first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment or disease progression, whicheer is earlier | |
Secondary | Maximum plasma concentration (Cmax) of IO-108 | Characterize the Cmax of IO-108 by successive sampling of blood at pre-specified time points | From the first dose of IO-108 until day 15 post-treatment | |
Secondary | Steady state concentration of IO-108 | Characterize steady state concentration of IO-108 by successive sampling of blood at pre-specified time points | From the second dose of IO-108 until the last treatment which is up to 2 years from the first treatment date | |
Secondary | Immunogenicity of IO-108 and IO-108+pembrolizumab | Determine the incidence/titer of anti-drug antibodies (ADAs) against IO-108 and pembrolizumab (in combination treatment) | From the first dose until 30 days after the last treatment | |
Secondary | Anti-tumor activity of IO-108 and IO-108+pembrolizumab | Determine preliminary rates of response after treatment with IO-108 | From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to estimated period of 48 months | |
Secondary | Determine disease control rates of IO-108 as monotherapy or in combination with either pembrolizumab or cemiplimab | Disease control rate is defined as the percentage of patients with complete response, partial response or stable disease maintained for at least 3 months | From the first dose of IO-108 until the last treatment which is up to 2 years from the first treatment or disease progression whichever is earlier |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04551885 -
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088004 -
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04020185 -
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05071846 -
MVX-ONCO-2 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05607199 -
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
|
Phase 1 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Active, not recruiting |
NCT06026254 -
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
|
Phase 1 | |
Recruiting |
NCT06032845 -
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)
|
Phase 2 | |
Recruiting |
NCT06144671 -
GT201 Injection For The Treatment Of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06398418 -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05276284 -
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04121442 -
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04221204 -
A Monotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03992326 -
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Terminated |
NCT05435339 -
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
Recruiting |
NCT06075849 -
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
|
Phase 1 | |
Recruiting |
NCT04092673 -
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
|
Phase 1/Phase 2 |